NBC Securities Inc. Raises Stake in IQVIA Holdings Inc. (NYSE:IQV)

NBC Securities Inc. lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 352,600.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,527 shares of the medical research company's stock after purchasing an additional 3,526 shares during the period. NBC Securities Inc.'s holdings in IQVIA were worth $621,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. JPMorgan Chase & Co. raised its position in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Brighton Jones LLC lifted its position in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after purchasing an additional 2,537 shares during the period. Chicago Partners Investment Group LLC lifted its position in shares of IQVIA by 65.8% in the 4th quarter. Chicago Partners Investment Group LLC now owns 1,580 shares of the medical research company's stock worth $323,000 after purchasing an additional 627 shares during the period. Spire Wealth Management grew its holdings in IQVIA by 42.9% during the 4th quarter. Spire Wealth Management now owns 733 shares of the medical research company's stock worth $144,000 after acquiring an additional 220 shares during the period. Finally, E. Ohman J or Asset Management AB raised its position in shares of IQVIA by 12.1% in the 4th quarter. E. Ohman J or Asset Management AB now owns 8,361 shares of the medical research company's stock worth $1,643,000 after acquiring an additional 900 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Up 3.2%

NYSE IQV traded up $4.70 on Friday, reaching $152.07. The company had a trading volume of 2,749,903 shares, compared to its average volume of 1,596,970. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $26.31 billion, a P/E ratio of 20.28, a P/E/G ratio of 1.99 and a beta of 1.28. The company's fifty day moving average is $148.07 and its 200 day moving average is $179.40. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same period last year, the firm earned $2.54 earnings per share. The firm's revenue was up 2.5% on a year-over-year basis. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

IQV has been the topic of several research analyst reports. Robert W. Baird cut their target price on IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Hsbc Global Res cut IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Royal Bank of Canada reiterated an "outperform" rating and issued a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Wall Street Zen downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Finally, HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and reduced their price target for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $226.32.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.